Report Detail
Global Rivastigmine Oral Market Insights, Forecast to 2025
- RnM3521257 |
- 14 June, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
The global Rivastigmine Oral market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Rivastigmine Oral market based on company, product type, end user and key regions.
This report studies the global market size of Rivastigmine Oral in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Rivastigmine Oral in these regions.
This research report categorizes the global Rivastigmine Oral market by top players/brands, region, type and end user. This report also studies the global Rivastigmine Oral market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Sun Pharmaceutical
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Market size by Product
1.5 mg Capsules
3 mg Capsules
4.5 mg Capsules
6 mg Capsules
2mg/ml Oral solution
Market size by End User
Alzheimer's disease
Parkinson's
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Rivastigmine Oral market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Rivastigmine Oral market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Rivastigmine Oral companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Rivastigmine Oral submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Rivastigmine Oral are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Rivastigmine Oral market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Rivastigmine Oral Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Rivastigmine Oral Market Size Growth Rate by Product
- 1.4.2 1.5 mg Capsules
- 1.4.3 3 mg Capsules
- 1.4.4 4.5 mg Capsules
- 1.4.5 6 mg Capsules
- 1.4.6 2mg/ml Oral solution
- 1.5 Market by End User
- 1.5.1 Global Rivastigmine Oral Market Size Growth Rate by End User
- 1.5.2 Alzheimer's disease
- 1.5.3 Parkinson's
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Rivastigmine Oral Market Size
- 2.1.1 Global Rivastigmine Oral Revenue 2014-2025
- 2.1.2 Global Rivastigmine Oral Sales 2014-2025
- 2.2 Rivastigmine Oral Growth Rate by Regions
- 2.2.1 Global Rivastigmine Oral Sales by Regions
- 2.2.2 Global Rivastigmine Oral Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Rivastigmine Oral Sales by Manufacturers
- 3.1.1 Rivastigmine Oral Sales by Manufacturers
- 3.1.2 Rivastigmine Oral Sales Market Share by Manufacturers
- 3.1.3 Global Rivastigmine Oral Market Concentration Ratio (CR5 and HHI)
- 3.2 Rivastigmine Oral Revenue by Manufacturers
- 3.2.1 Rivastigmine Oral Revenue by Manufacturers (2014-2019)
- 3.2.2 Rivastigmine Oral Revenue Share by Manufacturers (2014-2019)
- 3.3 Rivastigmine Oral Price by Manufacturers
- 3.4 Rivastigmine Oral Manufacturing Base Distribution, Product Types
- 3.4.1 Rivastigmine Oral Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Rivastigmine Oral Product Type
- 3.4.3 Date of International Manufacturers Enter into Rivastigmine Oral Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Rivastigmine Oral Sales by Product
- 4.2 Global Rivastigmine Oral Revenue by Product
- 4.3 Rivastigmine Oral Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Rivastigmine Oral Breakdown Data by End User
6 North America
- 6.1 North America Rivastigmine Oral by Countries
- 6.1.1 North America Rivastigmine Oral Sales by Countries
- 6.1.2 North America Rivastigmine Oral Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Rivastigmine Oral by Product
- 6.3 North America Rivastigmine Oral by End User
7 Europe
- 7.1 Europe Rivastigmine Oral by Countries
- 7.1.1 Europe Rivastigmine Oral Sales by Countries
- 7.1.2 Europe Rivastigmine Oral Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Rivastigmine Oral by Product
- 7.3 Europe Rivastigmine Oral by End User
8 Asia Pacific
- 8.1 Asia Pacific Rivastigmine Oral by Countries
- 8.1.1 Asia Pacific Rivastigmine Oral Sales by Countries
- 8.1.2 Asia Pacific Rivastigmine Oral Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Rivastigmine Oral by Product
- 8.3 Asia Pacific Rivastigmine Oral by End User
9 Central & South America
- 9.1 Central & South America Rivastigmine Oral by Countries
- 9.1.1 Central & South America Rivastigmine Oral Sales by Countries
- 9.1.2 Central & South America Rivastigmine Oral Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Rivastigmine Oral by Product
- 9.3 Central & South America Rivastigmine Oral by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Rivastigmine Oral by Countries
- 10.1.1 Middle East and Africa Rivastigmine Oral Sales by Countries
- 10.1.2 Middle East and Africa Rivastigmine Oral Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Rivastigmine Oral by Product
- 10.3 Middle East and Africa Rivastigmine Oral by End User
11 Company Profiles
- 11.1 Novartis
- 11.1.1 Novartis Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Novartis Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Novartis Rivastigmine Oral Products Offered
- 11.1.5 Novartis Recent Development
- 11.2 Sun Pharmaceutical
- 11.2.1 Sun Pharmaceutical Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Sun Pharmaceutical Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Sun Pharmaceutical Rivastigmine Oral Products Offered
- 11.2.5 Sun Pharmaceutical Recent Development
- 11.3 Mylan Pharmaceuticals
- 11.3.1 Mylan Pharmaceuticals Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Mylan Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Mylan Pharmaceuticals Rivastigmine Oral Products Offered
- 11.3.5 Mylan Pharmaceuticals Recent Development
- 11.4 Teva
- 11.4.1 Teva Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Teva Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Teva Rivastigmine Oral Products Offered
- 11.4.5 Teva Recent Development
- 11.5 Dr. Reddy's Laboratories
- 11.5.1 Dr. Reddy's Laboratories Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Dr. Reddy's Laboratories Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Dr. Reddy's Laboratories Rivastigmine Oral Products Offered
- 11.5.5 Dr. Reddy's Laboratories Recent Development
- 11.6 Orchid Healthcare
- 11.6.1 Orchid Healthcare Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Orchid Healthcare Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Orchid Healthcare Rivastigmine Oral Products Offered
- 11.6.5 Orchid Healthcare Recent Development
- 11.7 APOTEX
- 11.7.1 APOTEX Company Details
- 11.7.2 Company Business Overview
- 11.7.3 APOTEX Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 APOTEX Rivastigmine Oral Products Offered
- 11.7.5 APOTEX Recent Development
- 11.8 Alembic Pharmaceuticals
- 11.8.1 Alembic Pharmaceuticals Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Alembic Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Alembic Pharmaceuticals Rivastigmine Oral Products Offered
- 11.8.5 Alembic Pharmaceuticals Recent Development
- 11.9 MACLEODS
- 11.9.1 MACLEODS Company Details
- 11.9.2 Company Business Overview
- 11.9.3 MACLEODS Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 MACLEODS Rivastigmine Oral Products Offered
- 11.9.5 MACLEODS Recent Development
- 11.10 Cadila Pharmaceuticals
- 11.10.1 Cadila Pharmaceuticals Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Cadila Pharmaceuticals Rivastigmine Oral Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Cadila Pharmaceuticals Rivastigmine Oral Products Offered
- 11.10.5 Cadila Pharmaceuticals Recent Development
- 11.11 Aurobindo Pharma
- 11.12 Ajanta Pharma
12 Future Forecast
- 12.1 Rivastigmine Oral Market Forecast by Regions
- 12.1.1 Global Rivastigmine Oral Sales Forecast by Regions 2019-2025
- 12.1.2 Global Rivastigmine Oral Revenue Forecast by Regions 2019-2025
- 12.2 Rivastigmine Oral Market Forecast by Product
- 12.2.1 Global Rivastigmine Oral Sales Forecast by Product 2019-2025
- 12.2.2 Global Rivastigmine Oral Revenue Forecast by Product 2019-2025
- 12.3 Rivastigmine Oral Market Forecast by End User
- 12.4 North America Rivastigmine Oral Forecast
- 12.5 Europe Rivastigmine Oral Forecast
- 12.6 Asia Pacific Rivastigmine Oral Forecast
- 12.7 Central & South America Rivastigmine Oral Forecast
- 12.8 Middle East and Africa Rivastigmine Oral Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Rivastigmine Oral Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Rivastigmine Oral. Industry analysis & Market Report on Rivastigmine Oral is a syndicated market report, published as Global Rivastigmine Oral Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Rivastigmine Oral market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
